COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1201
https://www.valueinhealthjournal.com/article/S1098-3015(15)03277-5/fulltext
Title :
COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03277-5&doi=10.1016/j.jval.2015.09.1201
First page :
A462
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
699